Literature DB >> 25314250

Association of chronic hepatitis C infection with T-cell phenotypes in HIV-negative and HIV-positive women.

Mark H Kuniholm1, Xianhong Xie, Kathryn Anastos, Robert C Kaplan, Xiaonan Xue, Andrea Kovacs, Marion G Peters, Eric C Seaberg, Audrey L French, Mary A Young, Michael Augenbraun, Jeffrey A Martinson, Kristin A Bush, Alan L Landay, Howard D Strickler.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) viremia is thought to have broad systemic effects on the cellular immune system that go beyond its impact on just those T cells that are HCV specific. However, previous studies of chronic HCV and circulating T-cell subsets (activation and differentiation phenotypes) in HIV negatives used general population controls, rather than a risk-appropriate comparison group. Studies in HIV positives did not address overall immune status (total CD4⁺ count).
METHODS: We used fresh blood from HIV-positive and at-risk HIV-negative women, with and without chronic HCV, to measure percentages of activated CD4⁺ and CD8⁺ T cells, Tregs, and T-cell differentiation phenotypes (naive, central memory, effector memory (EM), and terminally differentiated effector). This included 158 HIV negatives and 464 HIV positives, of whom 18 and 63, respectively, were HCV viremic.
RESULTS: In multivariate models of HIV negatives, HCV viremia was associated with 25% fewer naive CD4⁺ (P = 0.03), 33% more EM CD4⁺ (P = 0.0002), and 37% fewer central memory CD8⁺ (P = 0.02) T cells. Among HIV positives, we observed only 1 of these 3 relationships: higher percentage of EM CD4⁺ among HCV viremic women. Furthermore, the association with EM CD4⁺ among HIV positives was limited to individuals with diminished immune status (total CD4⁺ count ≤500 cells/μL), as were associations of HCV viremia with higher percentages of activated CD4⁺ and Tregs. Among HIV positives with high CD4⁺ count, no significant associations were observed.
CONCLUSIONS: These data suggest that HCV viremia in HIV negatives is associated with accelerated T-cell differentiation, but among HIV positives, the impact of HCV viremia is less straightforward and varies by total CD4v count.

Entities:  

Mesh:

Year:  2014        PMID: 25314250      PMCID: PMC4197408          DOI: 10.1097/QAI.0000000000000310

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  40 in total

Review 1.  Failure of innate and adaptive immune responses in controlling hepatitis C virus infection.

Authors:  Robert Thimme; Marco Binder; Ralf Bartenschlager
Journal:  FEMS Microbiol Rev       Date:  2012-01-04       Impact factor: 16.408

2.  Frequency of human T regulatory cells in peripheral blood is significantly reduced by cryopreservation.

Authors:  Eyad Elkord
Journal:  J Immunol Methods       Date:  2009-06-16       Impact factor: 2.303

Review 3.  Immunology of hepatitis C virus infections.

Authors:  Michelle Spaan; Harry L A Janssen; Andre Boonstra
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-08       Impact factor: 3.043

4.  Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors.

Authors:  Mohammad M Sajadi; Roopa Pulijala; Robert R Redfield; Rohit Talwani
Journal:  AIDS       Date:  2012-09-24       Impact factor: 4.177

5.  Distributional characteristics of CD25 and CD127 on CD4+ T cell subsets in chronic HCV infection.

Authors:  Tao Shen; Xiangmei Chen; Qiang Xu; Fengmin Lu; Shuang Liu
Journal:  Arch Virol       Date:  2010-03-05       Impact factor: 2.574

6.  Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection.

Authors:  Nicole L Yonkers; Scott Sieg; Benigno Rodriguez; Donald D Anthony
Journal:  J Infect Dis       Date:  2011-01-10       Impact factor: 5.226

7.  Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization.

Authors:  Adriana Weinberg; Lin-Ye Song; Cynthia Wilkening; Anne Sevin; Bruce Blais; Raul Louzao; Dana Stein; Patricia Defechereux; Deborah Durand; Eric Riedel; Nancy Raftery; Renee Jesser; Betty Brown; M Fran Keller; Ruth Dickover; Elizabeth McFarland; Terence Fenton
Journal:  Clin Vaccine Immunol       Date:  2009-06-10

8.  High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment.

Authors:  Veronica D Gonzalez; Karolin Falconer; Kim G Blom; Olle Reichard; Birgitte Mørn; Alex Lund Laursen; Nina Weis; Annette Alaeus; Johan K Sandberg
Journal:  J Virol       Date:  2009-08-26       Impact factor: 5.103

9.  CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus.

Authors:  Andrea Kovacs; Lena Al-Harthi; Shawna Christensen; Wendy Mack; Mardge Cohen; Alan Landay
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

10.  Hepatitis C virus infection and the risk of coronary disease.

Authors:  Adeel A Butt; Wang Xiaoqiang; Matthew Budoff; David Leaf; Lewis H Kuller; Amy C Justice
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

View more
  5 in total

1.  The Association of Human Cytomegalovirus with Biomarkers of Inflammation and Immune Activation in HIV-1-Infected Women.

Authors:  Nell S Lurain; Barbara A Hanson; Anna L Hotton; Kathleen M Weber; Mardge H Cohen; Alan L Landay
Journal:  AIDS Res Hum Retroviruses       Date:  2015-10-22       Impact factor: 2.205

2.  Cardiovascular risk score associations with frailty in men and women with or at risk for HIV.

Authors:  Mark H Kuniholm; Elizabeth Vásquez; Allison A Appleton; Lawrence Kingsley; Frank J Palella; Matthew Budoff; Erin D Michos; Ervin Fox; Deborah Jones; Adaora A Adimora; Igho Ofotokun; Gypsyamber D'souza; Kathleen M Weber; Phyllis C Tien; Michael Plankey; Anjali Sharma; Deborah R Gustafson
Journal:  AIDS       Date:  2022-02-01       Impact factor: 4.632

3.  Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study.

Authors:  Seema N Desai; Jennifer L Dodge; Alan L Landay; Marshall J Glesby; Patricia S Latham; Maria C Villacres; Audrey L French; Stephen J Gange; Ruth M Greenblatt; Marion G Peters
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

4.  Both HCV Infection and Elevated Liver Stiffness Significantly Impacts on Several Parameters of T-Cells Homeostasis in HIV-Infected Patients.

Authors:  Clara Restrepo; Beatriz Álvarez; José L Valencia; Marcial García; María A Navarrete-Muñoz; José M Ligos; Alfonso Cabello; Laura Prieto; Sara Nistal; María Montoya; Miguel Górgolas; Norma Rallón; José M Benito
Journal:  J Clin Med       Date:  2020-09-15       Impact factor: 4.241

5.  Association of Hepatitis C Virus Infection With CD4/CD8 Ratio in HIV-Positive Women.

Authors:  Mark H Kuniholm; Thomas R OʼBrien; Ludmila Prokunina-Olsson; Michael Augenbraun; Michael Plankey; Roksana Karim; Monika Sarkar; Audrey L French; Chris Pierce; Howard D Strickler; Kathryn Anastos
Journal:  J Acquir Immune Defic Syndr       Date:  2016-06-01       Impact factor: 3.731

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.